Skip to main content
Welcome to
Sanofi
About us
About us
U.S. LEADERSHIP
Our Stories
Corporate Compliance
Corporate Compliance
California Compliance Law
Shannon Kelley
California Compliance Law - Sanofi Pasteur
Compliance Program for Sanofi Pasteur
Committed to Transparency
Sanofi Websites in the U.S.
Your Health
Your Health
Vaccines
Science & Innovation
Science & Innovation
Clinical Trials
INVESTIGATOR SPONSORED STUDIES (ISS)
Products & Resources
Products & Resources
Prescription Products
Vaccines Products
Vaccines Products
Yellow Fever Vaccine Information
Generics
Consumer Health (OTC) Products
U.S. Patents
Patient Support Services
Resources for Healthcare Providers
Colorado Disclosure
Vermont Disclosure
Our Responsibility
Our Responsibility
Corporate Social Responsibility
Access to Healthcare
Patient Advocacy at Sanofi in the U.S.
Patient Advocacy at Sanofi in the U.S.
Health Equity at Sanofi in the U.S.
2023 Health Equity Accelerator Awards: Application Guidelines
2022 Health Equity Accelerator Award Winners
Health Equity Accelerator Awards Aim to Expand Solutions for Bigger Impact
Patient Centered Healthcare Value Assessment
Diversity, Equity & Inclusion
Diversity, Equity & Inclusion
A Million Conversations: Addressing Disparities in Healthcare
Diversity in Clinical Trials
Employee Resource Groups
Supplier Diversity
Contributions and Giving
Contributions and Giving
TORCH Awards
Sponsorships
Philanthropic Donations
Healthcare Contributions
Independent Medical Education (IME/CME) Grants
Fellowships
Rare Genetic Disease Fellowships
Patient Assistance Foundations
Pricing Principles
Pricing Principles
2023 Pricing Principles Report
Clear Rationale for Pricing
Limited U.S. Price Increases
Continued Transparency in the U.S.
Prioritizing Patient Affordability
Healthy Planet
Careers
Careers
Benefits
Diversity
Postdoctoral Careers
Physician Careers
Students
Veterans
Investors
Media
Toggle navigation
Home
Press Releases
Subscribe
Social Media
Media Contacts
Press Releases
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Year
All Years
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Category
All Categories
Corporate News
Product News
Provention Bio archive
Vaccines News
Uncategorized
Keywords
Go
Advanced Search
Search
Search Headlines Only
Category
All Categories
Corporate News
Product News
Provention Bio archive
Vaccines News
Uncategorized
From
To
Asset Types
Video
Audio
Photos
Documents
Events
Standard
May 21, 2023
Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine
May 18, 2023
Sanofi Applauds Supreme Court Ruling Supporting Scientific Innovation by Striking Down Amgen's Asserted PCSK9 Patent Claims in Amgen v Sanofi
May 5, 2023
New late-breaking data at ATS 2023 demonstrate significant advancements across Dupixent® and broader respiratory pipeline
17 abstracts showcase new data for Dupixent, itepekimab and anti-IL-13/TSLP NANOBODY® molecule in COPD and asthma
May 1, 2023
Sanofi Canada et Diabetes Care Community annoncent une collaboration pour soutenir le parcours de bien-être émotionnel des Canadiens et Canadiennes vivant avec le diabète
Apr 27, 2023
Sanofi completes acquisition of Provention Bio, Inc.
Apr 4, 2023
Sanofi Breaks Ground on State-of-the-Art Facility in Swiftwater for Sustainable Production of Pandemic Flu Vaccines
Mar 23, 2023
Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial
First and only biologic to demonstrate clinically meaningful and statistically significant reduction (30%) in exacerbations compared to placebo
Mar 18, 2023
Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis
More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks
Mar 13, 2023
Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call
Mar 7, 2023
Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review
Show
5
10
25
50
100
per page
«
1
2
3
4
5
6
7
8
9
…
111
»
Print
Email page
RSS